![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, November 03, 2009 8:58:04 AM
8:02a ET November 3, 2009 (GlobeNewswire)
XOMA Ltd. (Nasdaq:XOMA) and Kaketsuken have entered into a collaboration involving multiple proprietary XOMA antibody research and development technologies, including a new XOMA antibody phage display library, and a suite of integrated information and data management systems. Subject to certain technical verification required under the collaboration agreement, Kaketsuken has agreed to pay XOMA a fee of $8 million and XOMA will be entitled to milestone payments and royalties on product sales. Founded in 1926 in Japan as the Chemo-Sero-Therapeutic Research Institute, Kaketsuken, a research foundation with current annual revenues of approximately US $350 million, has blood plasma products, vaccines and therapeutics and is developing therapeutic solutions for infectious, and other diseases.
"Antibody technologies are increasingly important in the development of novel therapeutics for a wide range of diseases so it is essential to find the best technologies and partners to maximize the chances for success," said Dr. Hiroshi Mizokami, Executive Director of Kaketsuken. "With XOMA's successful record of antibody candidates and drug development relationships, we are confident that they can provide us with the technologies we need to accelerate our antibody development programs. We look forward to a mutually beneficial relationship."
The centerpiece of the collaboration is access to a highly diverse antibody phage display library constructed by XOMA. Phage display libraries enable rapid generation and screening of large numbers of candidate antibodies and antibody fragments to select for optimal binding and other characteristics. XOMA's new, proprietary antibody phage display library is one of a new category of libraries being developed by XOMA scientists to overcome existing limitations in library design by combining very high diversity and "best in class" techniques with XOMA's proprietary and patent-protected technologies to enable the selection of antibodies with very specific and high affinity binding and potency characteristics to an antigen of choice.
"We are pleased to collaborate with Kaketsuken, an innovator in immunology and developer of the DPT vaccine," said Steven B. Engle, XOMA's Chairman and Chief Executive Officer. "This is the third technology collaboration XOMA has initiated this year, which combined are expected to result in fee revenue totaling $43 million and potential future milestone and royalty payments. We look forward to additional agreements that demonstrate the value of our extensive antibody expertise and increase the return on our research and development investment."
Recent XOMA News
- XOMA Declares Quarterly Preferred Stock Dividends • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher • GlobeNewswire Inc. • 06/12/2024 11:30:00 AM
- XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2% • GlobeNewswire Inc. • 04/30/2024 11:30:00 AM
- XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) • GlobeNewswire Inc. • 04/25/2024 11:30:00 AM
- Actym Therapeutics Appoints Thomas Smart as CEO • PR Newswire (US) • 04/24/2024 01:00:00 PM
- XOMA Corporation Announces Closing of Tender Offer • GlobeNewswire Inc. • 04/03/2024 01:00:00 PM
- XOMA Declares Quarterly Preferred Stock Dividends • GlobeNewswire Inc. • 03/21/2024 11:30:00 AM
- XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. • GlobeNewswire Inc. • 03/19/2024 08:05:00 PM
- XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value • GlobeNewswire Inc. • 03/08/2024 12:30:00 PM
- XOMA to Present at Upcoming Investor Conferences in March • GlobeNewswire Inc. • 02/28/2024 12:30:00 PM
- XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right • GlobeNewswire Inc. • 02/16/2024 01:00:00 PM
- XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition • GlobeNewswire Inc. • 01/18/2024 01:30:00 PM
- Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol • Dow Jones News • 01/11/2024 09:50:00 PM
- FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx • GlobeNewswire Inc. • 01/11/2024 09:05:00 PM
- XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors • GlobeNewswire Inc. • 01/08/2024 12:30:00 PM
- XOMA Announces Stock Repurchase Program of up to $50 Million • GlobeNewswire Inc. • 01/02/2024 12:30:00 PM
- XOMA Declares Quarterly Preferred Stock Dividends • GlobeNewswire Inc. • 12/20/2023 12:30:00 PM
- XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties • GlobeNewswire Inc. • 12/19/2023 12:30:00 PM
- XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value • GlobeNewswire Inc. • 11/07/2023 12:30:00 PM
- XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) • GlobeNewswire Inc. • 10/31/2023 11:30:00 AM
- XOMA Declares Quarterly Preferred Stock Dividends • GlobeNewswire Inc. • 09/25/2023 11:30:00 AM
- XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/06/2023 11:30:00 AM
- XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy • GlobeNewswire Inc. • 08/08/2023 11:30:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM